NASDAQ
NERV

Minerva Neurosciences Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Minerva Neurosciences Inc Stock Price

Vitals

Today's Low:
$7.9
Today's High:
$8.3
Open Price:
$8.01
52W Low:
$1.26
52W High:
$14.7
Prev. Close:
$8
Volume:
64338

Company Statistics

Market Cap.:
$55.95 million
Book Value:
-1.789
Revenue TTM:
$0
Operating Margin TTM:
0%
Gross Profit TTM:
$-16838947
Profit Margin:
0%
Return on Assets TTM:
-19.06%
Return on Equity TTM:
-675.09%

Company Profile

Minerva Neurosciences Inc had its IPO on 2014-07-01 under the ticker symbol NERV.

The company operates in the Healthcare sector and Biotechnology industry. Minerva Neurosciences Inc has a staff strength of 9 employees.

Stock update

Shares of Minerva Neurosciences Inc opened at $8.01 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $7.9 - $8.3, and closed at $8.1.

This is a +1.25% increase from the previous day's closing price.

A total volume of 64,338 shares were traded at the close of the day’s session.

In the last one week, shares of Minerva Neurosciences Inc have slipped by -3.34%.

Minerva Neurosciences Inc's Key Ratios

Minerva Neurosciences Inc has a market cap of $55.95 million, indicating a price to book ratio of 2.6783 and a price to sales ratio of 1.868.

In the last 12-months Minerva Neurosciences Inc’s revenue was $0 with a gross profit of $-16838947 and an EBITDA of $-26332688. The EBITDA ratio measures Minerva Neurosciences Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Minerva Neurosciences Inc’s operating margin was 0% while its return on assets stood at -19.06% with a return of equity of -675.09%.

In Q2, Minerva Neurosciences Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Minerva Neurosciences Inc’s PE and PEG Ratio

Forward PE
11.2108
Trailing PE
0
PEG
0

Its diluted EPS in the last 12-months stands at $-5.11 per share while it has a forward price to earnings multiple of 11.2108 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Minerva Neurosciences Inc’s profitability.

Minerva Neurosciences Inc stock is trading at a EV to sales ratio of 0.0345 and a EV to EBITDA ratio of 1.3952. Its price to sales ratio in the trailing 12-months stood at 1.868.

Minerva Neurosciences Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$67.14 million
Total Liabilities
$1.91 million
Operating Cash Flow
$0
Capital Expenditure
$0
Dividend Payout Ratio
0%

Minerva Neurosciences Inc ended 2024 with $67.14 million in total assets and $0 in total liabilities. Its intangible assets were valued at $67.14 million while shareholder equity stood at $-12510901.00.

Minerva Neurosciences Inc ended 2024 with $0 in deferred long-term liabilities, $1.91 million in other current liabilities, 699.00 in common stock, $-379972523.00 in retained earnings and $14.87 million in goodwill. Its cash balance stood at $51.80 million and cash and short-term investments were $51.80 million. The company’s total short-term debt was $0 while long-term debt stood at $0.

Minerva Neurosciences Inc’s total current assets stands at $52.23 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $298251.00 and inventory worth $0.

In 2024, Minerva Neurosciences Inc's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Minerva Neurosciences Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$8.1
52-Week High
$14.7
52-Week Low
$1.26
Analyst Target Price
$11

Minerva Neurosciences Inc stock is currently trading at $8.1 per share. It touched a 52-week high of $14.7 and a 52-week low of $14.7. Analysts tracking the stock have a 12-month average target price of $11.

Its 50-day moving average was $9.31 and 200-day moving average was $4.98 The short ratio stood at 1.61 indicating a short percent outstanding of 0%.

Around 2618.2% of the company’s stock are held by insiders while 3093.6% are held by institutions.

Frequently Asked Questions About Minerva Neurosciences Inc

The stock symbol (also called stock or share ticker) of Minerva Neurosciences Inc is NERV

The IPO of Minerva Neurosciences Inc took place on 2014-07-01

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$73.04
0.42
+0.58%
$216.2
-13.1
-5.71%
$10.39
0
0%
$9.71
-0.03
-0.31%
$8
0.13
+1.65%
$5.67
-0.08
-1.39%
$0
-0.01
-93.94%
$331.77
-6.17
-1.83%
$1.6
-0.04
-2.44%
$2.26
0.1
+4.63%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson’s disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Address

1601 Trapelo Road, Waltham, MA, United States, 02451